Benzinga · Aug 6, 2026
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
BI
NASDAQ · BIOA
BioAge Labs, Inc.
Healthcare · Biotechnology
$9.50
Down-$0.15 (-1.55%)
Updated Sep 1, 2026, 7:03 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 458.05M
- P/E ratio
- -6.04
- Dividend yield
- 0.00%
- 52-week range
- $8.65 – $25.96
- Volume
- 1.03M
- Avg. volume
- 403.63K
Price performance
BIOA price history
1M range · 21 trading sessions · Daily adjusted prices
BIOA closed at $9.50 after 21 trading sessions, down 11.87% for the selected period.
- Last close
- $9.50
- Period change
- -11.87%
- Period low
- $9.38
- Period high
- $11.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $9.61 | $9.63 | $9.20 | $9.50 | 1.03M |
| Aug 28, 2026 | $10.06 | $10.25 | $9.595 | $9.65 | 452.19K |
| Aug 27, 2026 | $9.93 | $10.23 | $9.80 | $10.08 | 475.43K |
| Aug 26, 2026 | $10.03 | $10.03 | $9.76 | $9.84 | 504.28K |
| Aug 25, 2026 | $9.55 | $10.13 | $9.55 | $10.11 | 499.33K |
| Aug 24, 2026 | $9.57 | $9.65 | $9.16 | $9.38 | 661.58K |
| Aug 21, 2026 | $9.78 | $9.9164 | $9.48 | $9.48 | 453.45K |
| Aug 20, 2026 | $10.64 | $10.725 | $9.63 | $9.69 | 776.79K |
| Aug 19, 2026 | $10.69 | $10.88 | $10.38 | $10.75 | 412.25K |
| Aug 18, 2026 | $10.31 | $10.75 | $10.19 | $10.46 | 478.46K |
| Aug 17, 2026 | $10.60 | $10.71 | $10.145 | $10.40 | 671.94K |
| Aug 14, 2026 | $10.37 | $10.63 | $10.10 | $10.60 | 444.37K |
| Aug 13, 2026 | $10.62 | $10.86 | $10.37 | $10.43 | 536.93K |
| Aug 12, 2026 | $10.78 | $10.95 | $10.43 | $10.48 | 614.58K |
| Aug 11, 2026 | $11.49 | $11.55 | $10.44 | $10.67 | 761.07K |
| Aug 10, 2026 | $11.70 | $11.89 | $11.25 | $11.45 | 594.39K |
| Aug 7, 2026 | $11.40 | $11.94 | $11.2286 | $11.72 | 953.53K |
| Aug 6, 2026 | $10.902 | $11.37 | $10.50 | $11.27 | 844.66K |
| Aug 5, 2026 | $11.30 | $11.595 | $10.89 | $10.98 | 1.13M |
| Aug 4, 2026 | $10.69 | $11.47 | $10.09 | $11.20 | 2.37M |
| Aug 3, 2026 | $9.50 | $10.96 | $9.18 | $10.78 | 3.53M |
Latest BIOA news
The latest Smart Investors Daily articles mentioning BIOA.
Stock researchCompany · Overview
BIOA research
Overview
Company profile and research snapshot.
Company profile
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | BTIG | Buy | — |
| Aug 3, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | Needham | Buy | — |
| May 27, 2026 | Roth Capital | Buy | — |
| May 13, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 5, 2026
Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60) per share from the
Benzinga · Aug 3, 2026
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
Benzinga · Jul 31, 2026
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
